The joint project will provide a more efficient approach to prescribe, obtain, and administer therapy necessary for patients to better manage their disease and symptoms.
ZappRx's cloud-based platform streamlines what is currently a multi-step, manual prescribing process, often involving numerous platforms for each of several treatments, into a single, digitally-enabled format. This allows providers who treat severe asthma to focus more on patient care.
The company said it streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for ordering specialty drugs, including pharmacy information, payer/prior authorisation requirements, and relevant clinical history.
ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls.
The platform currently is live in Pulmonary (including Cystic Fibrosis, Pulmonary Arterial Hypertension, and Idiopathic Pulmonary Fibrosis), Severe Asthma, Cardiology (including Hyperlipidemia and Congestive Heart Failure), and Gastroenterology (including Crohn's Disease and Ulcerative Colitis).
As the company grows, ZappRx plans to expand into other areas, including Rheumatology, Neurology, and Oncology.
Connect with ZappRx on Twitter and LinkedIn.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review